ICP-248

ICP-248 is a small-molecule drug developed by Beijing InnoCare Pharma Tech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06378138 (ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (APEX-03)), in mantle cell lymphoma and chronic lymphocytic leukaemia. The largest, NCT06378138, plans to enrol 226 participants with primary completion expected 2030-11-25. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.